Economic evaluation of therapeutic cancer vaccines and immunotherapy: A systematic review

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 11, 2014, Pages 3415-3424

  Geynisman, Daniel M ^a   Chien, Chun Ru ^b,c   Smieliauskas, Fabrice ^d   Shen, Chan ^e   Shih, Ya Chen Tina ^d,e  

^a FOX CHASE CANCER CENTER   (United States)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BEVACIZUMAB; BRENTUXIMAB VEDOTIN; CANCER VACCINE; CATUMAXOMAB; CETUXIMAB; IBRITUMOMAB TIUXETAN; IPILIMUMAB; OBINUTUZUMAB; OFATUMUMAB; PANITUMUMAB; PERTUZUMAB; RITUXIMAB; SIPULEUCEL T; TOSITUMOMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; CYTOKINE; MONOCLONAL ANTIBODY;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG SAFETY; ECONOMIC EVALUATION; HUMAN; MONOTHERAPY; NONHODGKIN LYMPHOMA; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; TREATMENT INDICATION; COST BENEFIT ANALYSIS; ECONOMICS; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES;

ANTIBODIES, MONOCLONAL; CANCER VACCINES; COST-BENEFIT ANALYSIS; CYTOKINES; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 84921753797     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.29407     Document Type: Review

References (64)

1. Finn OJ. Cancer immunology. The New England journal of medicine 2008; 358:2704-15.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74.
3. Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011; 29:4828-36.
4. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. The New England journal of medicine 1998; 338:1272-8.
5. Eggermont AM, Suciu S, Testori A, Santinami M, Kruit WH, Marsden J, et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012; 30:3810-8.
6. Darcy PK, Neeson P, Yong CS, Kershaw MH. Manipulating immune cells for adoptive immunotherapy of cancer. Current opinion in immunology 2014; 27C:46-52.
7. Ferris RL, Jaffee EM, Ferrone S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010; 28:4390-9.
8. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine 2010; 363:711-23.
9. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. The New England journal of medicine 2010; 363:411-22.
10. Shih YC, Ganz PA, Aberle D, Abernethy A, Bekelman J, Brawley O, et al. Delivering high-quality and affordable care throughout the cancer care continuum. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2013; 31:4151-7.
11. Smith TJ, Hillner BE. Bending the cost curve in cancer care. The New England journal of medicine 2011; 364:2060-5.
12. Oldham RK, Dillman RO. Monoclonal antibodies in cancer therapy: 25 years of progress. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008; 26:1774-7.
13. Carroll J. New immunotherapies for cancer yield exciting results but high cost. Managed care (Langhorne, Pa) 2013; 22:54-6.
14. Simoens S. Pharmaco-economic aspects of sipuleucel- T. Human vaccines & immunotherapeutics 2012; 8:506-8.
15. http://www.washingtonpost.com/wp-dyn/content/article/2010/11/07/AR2010110705205.html.
16. Centers for Medicare and Medicaid Services. Proposed decision memo for autologous cellular immunotherapy treatment of metastatic prostate cancer (CAG- 00422N). March 30, 2011. (http://www.cms.gov/medi care-coverage-database/details/nca-proposed-decisionmemo. aspx?NCAId=247&ver=10&NcaName=Autolo gous+Cellular+Immunotherapy+Treatment+of+Meta static+Prostate+Cancer&bc=BEAAAAAAEAAA&.).
17. Bach PB. Limits on Medicare's ability to control rising spending on cancer drugs. The New England journal of medicine 2009; 360:626-33.
18. Bach PB. Reforming the payment system for medical oncology. JAMA: the journal of the American Medical Association 2013; 310:261-2.
19. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine 2009; 6:e1000097.
20. Papaioannou D, Rafia R, Rathbone J, Stevenson M, Buckley Woods H, Stevens J. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation. Health technology assessment (Winchester, England) 2012; 16:1-253, iii-iv.
21. Auweiler PW, Muller D, Stock S, Gerber A. Cost effectiveness of rituximab for non-Hodgkin's lymphoma: a systematic review. PharmacoEconomics 2012; 30:537-49.
22. Parkinson B, Pearson SA, Viney R. Economic evaluations of trastuzumab inHER2-positive metastatic breast cancer: a systematic review and critique. The European journal of health economics : HEPAC : health economics in prevention and care 2014; 15:93-112.
23. Hoyle M, Crathorne L, Peters J, Jones-Hughes T, Cooper C, Napier M, et al. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with nonoxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model. Health technology assessment (Winchester, England) 2013; 17:1-237.
24. Lange A, Prenzler A, Frank M, Kirstein M, Vogel A, von der Schulenburg JM. A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer. European journal of cancer 2014;50:40-9.
25. Klemm J, Mehr SR. Prostate cancer. The American journal of managed care 2012; 18:SP119-21.
26. Vasani D, Josephson DY, Carmichael C, Sartor O, Pal SK. Recent advances in the therapy of castration-resistant prostate cancer: the price of progress. Maturitas 2011; 70:194-6.
27. Scott WG, Scott HM. Economic evaluation of third-line treatment with alemtuzumab for chronic lymphocytic leukaemia. Clinical drug investigation 2007; 27:755-64.
28. Jarkowski A, 3rd, Nestico JS, Vona KL, Khushalani NI. Dose rounding of ipilimumab in adult metastatic melanoma patients results in significant cost savings. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2014; 20:47-50.
29. Lu L, Peters J, Roome C, Stein K. Cost-effectiveness of alemtuzumab for T-cell prolymphocytic leukemia. International journal of technology assessment in health care 2012; 28:241-8.
30. Barzey V, AtkinsMB, Garrison LP, Asukai Y, Kotapati S, Penrod JR. Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis. Journal ofmedical economics 2013; 16:202-12.
31. Holko P, Kawalec P. Economic evaluation of sipuleucel- T immunotherapy in castration-resistant prostate cancer. Expert review of anticancer therapy 2014; 14:63-73.
32. Hoyle M, Crathorne L, Garside R, Hyde C. Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK. Health technology assessment (Winchester, England) 2011; 15 Suppl 1:61-7.
33. Maloney DG. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005; 23:6421-8.
34. Shih YC, Xu Y, Dong W, Smieliauskas F, Giordano S, Shen Y. First do no harm: population-based study shows non-evidence-based trastuzumab prescription may harm elderly women with breast cancer. Breast cancer research and treatment 2014; 144:417-25.
35. Shih YC, Halpern MT. Economic evaluations of medical care interventions for cancer patients: how, why, and what does it mean? CA: a cancer journal for clinicians 2008; 58:231-44.
36. Malin JL. Wrestling with the high price of cancer care: should we control costs by individuals' ability to pay or society's willingness to pay? Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010; 28:3212-4.
37. Ramsey S, Blough D, Kirchhoff A, Kreizenbeck K, Fedorenko C, Snell K, et al. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health affairs 2013; 32:1143-52.
38. Ubel PA, Abernethy AP, Zafar SY. Full disclosure-out-of- pocket costs as side effects. The New England journal of medicine 2013; 369:1484-6.
39. IOM. Delivering high-quality cancer care: Charting a new course for a system in crisis. Washington, DC: Institute of Medicine, 2013.
40. Long-Term Survival Achieved in Unfavorable Risk mRCC Patients Treated With a Combination of Autologous Immunotherapy (AGS-003) Plus Sunitinib A. Amin, A.Z., Dudek, G., Jha2, T., Logan, R.S., Lance, J.M., Holzbeierlein, V.A., Master, S.K., Pal, J.J., Knox, L., Karsh, D., Plessinger, C.A., Nicolette, R.A. Figlin, AGS-003-006 Study Group. ASCO 2014 Genitourinary Cancers Symposium - May 30-June 3, 2014 - Chicago, IL.
41. Lubaroff DM. Prostate cancer vaccines in clinical trials. Expert review of vaccines 2012; 11:857-68.
42. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PDL1 antibody in patients with advanced cancer. The New England journal of medicine 2012; 366:2455-65.
43. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. The New England journal of medicine 2013; 369:122-33.
44. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. The New England journal of medicine 2013; 369:134-44.
45. RestifoNP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nature reviews Immunology 2012; 12:269-81.
46. Eggermont A, Robert C, Soria JC, Zitvogel L. Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors. Oncoimmunology 2014; 3:e27560.
47. Maldonado L, Teague JE, Morrow MP, Jotova I, Wu TC, Wang C, et al. Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions. Science translational medicine 2014; 6:221ra13.
48. Liu J, Kosinska A, Lu M, Roggendorf M. New therapeutic vaccination strategies for the treatment of chronic hepatitis B. Virologica Sinica 2014; 29:10-6.
49. Promising New Cancer Drugs Empower the Body's Own Defense System. ANDREW POLLACK. Published: June 3, 2013 New York Times.
50. Breaking Through Cancer's Shield. GINA KOLATA Published: October 14, 2013.
51. Plumridge, Hester. "Drug Firms Focus on Advanced Melanoma," Wall Street Journal 03/23/2014
52. McCaughan, Michael. "Testing A New Model For Personalized Drug Development,", The RPM Report December 2013.
53. Cheema PK, Gavura S, Migus M, Godman B, Yeung L, Trudeau ME. International variability in the reimbursement of cancer drugs by publically funded drug programs. Current oncology 2012; 19:e165-76.
54. Maas, Angela. "Advanced RCC Gains Scrutiny as More Drugs Are Approved For It," Specialty Pharmacy News 9(4): April 2012.
55. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
56. http://www.ema.europa.eu/ema/.
57. Glanville J, Paisley S. Identifying economic evaluations for health technology assessment. International journal of technology assessment in health care 2010; 26:436-40.
58. Health Information Research Unit, McMaster University, http://hiru.mcmaster.ca/hiru/HIRU-Hedges-MEDLINE-Strategies.aspx, accessed on 2014/1/11.
59. Shen C, Chien CR, Geynisman DM, Smieliauskas F, Shih YC. A review of economic impact of targeted oral anticancer medications. Expert review of pharmacoeconomics & outcomes research 2014; 14:45-69.
60. http://www.ncbi.nlm.nih.gov/pubmed, accessed 2014/ 1/28.
61. http://www.thecochrancelibrary.com/view/0/index/ html, via institutional account, accessed 2014/2/6.
62. http://www.journalslibrary.nihr.ac.uk/search?collection= netscc-journals&form=advanced&, accessed 2014/2/6
63. Consumer Price Index. [cited 2014 Apr 12]; Available from: http://www.bls.gov/cpi/.
64. IMF. World Economic Outlook Database. [cited 2014 Apr 12]; Available from: http://www.imf.org/external/ pubs/ft/weo/2014/01/weodata/index.aspx.